- Home
- SAFE vs MLYS Comparison
SAFE vs MLYS Comparison
Compare SAFE & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- MLYS
- Stock Information
- Founded
- SAFE 2016
- MLYS 2019
- Country
- SAFE United States
- MLYS United States
- Employees
- SAFE N/A
- MLYS N/A
- Industry
- SAFE Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- SAFE Real Estate
- MLYS Health Care
- Exchange
- SAFE Nasdaq
- MLYS Nasdaq
- Market Cap
- SAFE 1.1B
- MLYS 1.0B
- IPO Year
- SAFE 2017
- MLYS 2023
- Fundamental
- Price
- SAFE $15.34
- MLYS $16.12
- Analyst Decision
- SAFE Buy
- MLYS Strong Buy
- Analyst Count
- SAFE 8
- MLYS 3
- Target Price
- SAFE $23.13
- MLYS $33.00
- AVG Volume (30 Days)
- SAFE 326.7K
- MLYS 801.2K
- Earning Date
- SAFE 07-28-2025
- MLYS 05-12-2025
- Dividend Yield
- SAFE 4.56%
- MLYS N/A
- EPS Growth
- SAFE N/A
- MLYS N/A
- EPS
- SAFE 1.46
- MLYS N/A
- Revenue
- SAFE $391,206,000.00
- MLYS N/A
- Revenue This Year
- SAFE $0.20
- MLYS N/A
- Revenue Next Year
- SAFE $4.76
- MLYS N/A
- P/E Ratio
- SAFE $10.44
- MLYS N/A
- Revenue Growth
- SAFE 2.64
- MLYS N/A
- 52 Week Low
- SAFE $13.68
- MLYS $8.24
- 52 Week High
- SAFE $28.80
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- SAFE 50.25
- MLYS 57.84
- Support Level
- SAFE $14.73
- MLYS $15.27
- Resistance Level
- SAFE $15.36
- MLYS $16.43
- Average True Range (ATR)
- SAFE 0.38
- MLYS 0.88
- MACD
- SAFE 0.07
- MLYS -0.06
- Stochastic Oscillator
- SAFE 74.47
- MLYS 63.81
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.